Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.

PloS one - 1 Jan 2014

Curl Patti, Vujic Igor, van 't Veer Laura J, Ortiz-Urda Susana, Kahn James G

Abstract excerpt

PURPOSE: Genetically-targeted therapies are both promising and costly advances in the field of oncology. Several treatments for metastatic melanoma with a mutation in the BRAF gene have been approved. They extend life but are more expensive than the previous standard of care (dacarbazine). Vemurafenib, the first drug in this class, costs $13,000 per month ($207,000 for a patient with median survival). Patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cost-Benefit Analysis
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Statistical

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Quality of Life

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25198196
DOI: 10.1371/journal.pone.0107255
PMCID: PMC4157865

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.PMID 25198196Read ↗

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced MelanomaSemantic proximity Read ↗

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced MelanomaSemantic proximity Read ↗

Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.Semantic proximity Read ↗

Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.Semantic proximity Read ↗

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.Semantic proximity Read ↗

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.Semantic proximity Read ↗

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.Semantic proximity Read ↗

Analysis of Cost-Effectiveness of Trametinib Plus Dabrafenib as First-Line Therapy for Metastatic BRAF V600-Mutated Melanoma in ChinaSemantic proximity Read ↗

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Semantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.